Advancing the global public health agenda for NAFLD: a consensus statement
Open accessThe DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects approximately one-quarter of the global adult population, causing a substantial burden of ill health with wide-ranging social and economic implications. It is a multisystem disease and is considered the hepatic component of metabolic syndrome. Unlike other highly prevalent conditions, NAFLD has received little attention from the global public health community. Health system and public health responses to NAFLD have been weak and fragmented, and, despite its pervasiveness, NAFLD is largely unknown outside hepatology and gastroenterology. There is only a nascent global public health movement addressing NAFLD, and the disease is absent from nearly all national and international strategies and policies for non-communicable diseases, including obesity. In this global Delphi study, a multidisciplinary group of experts developed consensus statements and recommendations, which a larger group of collaborators reviewed over three rounds until consensus was achieved. The resulting consensus statements and recommendations address a broad range of topics — from epidemiology, awareness, care and treatment to public health policies and leadership — that have general relevance for policy-makers, health-care practitioners, civil society groups, research institutions and affected populations. These recommendations should provide a strong foundation for a comprehensive public health response to NAFLD. Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease with a substantial burden worldwide. In this Consensus Statement, a global multidisciplinary group of experts develop consensus statements and recommendations addressing a broad range of topics on NAFLD to raise awareness and spur action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Self-citationChalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Self-citationGlobal Burden of Disease Cancer Collaboration, Fitzmaurice, C., Allen, C., Barber, R. M., Barregard, L., Bhutta, Z. A., Brenner, H., Dicker, D. J., Chimed-Orchir, O., Dandona, R., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5688 · Cited by 6,215
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
Self-citationEASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Self-citation2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease
Eslam, M., Sanyal, A. J., George, J., Sanyal, A., Neuschwander-Tetri, B., Tiribelli, C., Kleiner, D. E., Brunt, E., Bugianesi, E., Yki-Järvinen, H., et al. (2020) · Gastroenterology · doi:10.1053/j.gastro.2019.11.312 · Cited by 3,286
Self-citationExpanding consensus in portal hypertension
de Franchis, R. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.05.022 · Cited by 3,078
Research works printed but not linked: 2
- Lazarus, J. V. et al. The global non-alcoholic fatty liver disease (NAFLD) preparedness index: are countries ready to tackle the challenge? Int. Liver Congr. 75 (Suppl. 2), 23–26 (2021).
- Grime, M. M. & Wright, G. in Wiley StatsRef: Statistics Reference Online 1–6 (Wiley, 2011).
Cited by
Younossi, Z. M., Golabi, P., Paik, J. M., Henry, A., Van Dongen, C., & Henry, L. (2023) · Hepatology · doi:10.1097/hep.0000000000000004 · Cited by 3,383
Self-citationVogel, A., Meyer, T., Sapisochin, G., Salem, R., & Saborowski, A. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01200-4 · Cited by 2,427
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
“People with type 2 diabetes frequently have NAFLD and are at increased risk for progression to more severe stages of liver disease, including NASH, hepatic fibrosis and cirrhosis [290].”
Gut-liver axis: Pathophysiological concepts and clinical implications
Tilg, H., Adolph, T. E., & Trauner, M. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.09.017 · Cited by 843
Self-citationGlobal epidemiology of cirrhosis — aetiology, trends and predictions
Huang, D. Q., Terrault, N. A., Tacke, F., Gluud, L. L., Arrese, M., Bugianesi, E., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00759-2 · Cited by 839
Self-citationCurrent status and future trends of the global burden of MASLD
Miao, L., Targher, G., Byrne, C. D., Cao, Y.-Y., & Zheng, M.-H. (2024) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2024.02.007 · Cited by 781
Self-citationChanging epidemiology, global trends and implications for outcomes of NAFLD
Wong, V. W.-S., Ekstedt, M., Wong, G. L.-H., & Hagström, H. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.036 · Cited by 765
Self-citationGlobal Incidence and Prevalence of Nonalcoholic Fatty Liver Disease
Teng, M. L., Ng, C. H., Huang, D. Q., Chan, K. E., Tan, D. J., Lim, W. H., Yang, J. D., Tan, E., & Muthiah, M. D. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0365 · Cited by 727
“This serves as a call to action for greater political will and resources directed toward combating metabolic risk factors for NAFLD, at a regional and global level.(64,65)”
BackgroundHuang, D. Q., Singal, A. G., Kono, Y., Tan, D. J. H., El-Serag, H. B., & Loomba, R. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.003 · Cited by 534
Self-citationReply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature
Lazarus, J. V., Newsome, P. N., Francque, S. M., Kanwal, F., Terrault, N. A., & Rinella, M. E. (2024) · Hepatology · doi:10.1097/hep.0000000000000696 · Cited by 438
Self-citationMAFLD: How is it different from NAFLD?
Gofton, C., Upendran, Y., Zheng, M.-H., & George, J. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0367 · Cited by 423
“Despite the histopathological premise for the term NAFLD and advances in understanding the pathophysiological basis of the disease with many patient and healthcare suggestions for a name change, no new terminology has been developed and NAFLD has subsisted in the literature for decades.(24) Moreover, utilization of th…”
BackgroundSelf-citationNAFLD: Mechanisms, Treatments, and Biomarkers
Nassir, F. (2022) · Biomolecules · doi:10.3390/biom12060824 · Cited by 405
Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment
Llovet, J. M., Willoughby, C. E., Singal, A. G., Greten, T. F., Heikenwälder, M., El-Serag, H. B., Finn, R. S., & Friedman, S. L. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00754-7 · Cited by 354
Cusi, K., Abdelmalek, M. F., Apovian, C. M., Balapattabi, K., Bannuru, R. R., Barb, D., Bardsley, J. K., Beverly, E. A., Corbin, K. D., ElSayed, N. A., et al. (2025) · Diabetes Care · doi:10.2337/dci24-0094 · Cited by 332
Self-citationGut symbionts alleviate MASH through a secondary bile acid biosynthetic pathway
Nie, Q., Luo, X., Wang, K., Ding, Y., Jia, S., Zhao, Q., Li, M., Zhang, J., Zhuo, Y., Lin, J., et al. (2024) · Cell · doi:10.1016/j.cell.2024.03.034 · Cited by 326
Self-citationLiver diseases: epidemiology, causes, trends and predictions
Gan, C., Yuan, Y., Shen, H., Gao, J., Kong, X., Che, Z., Guo, Y., Wang, H., Dong, E., & Xiao, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02072-z · Cited by 310
“16,86 These diseases often progress asymptomatically, complicating early detection and treatment.”
Le, M. H., Le, D. M., Baez, T. C., Wu, Y., Ito, T., Lee, E. Y., Lee, K., Stave, C. D., Henry, L., Barnett, S. D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.040 · Cited by 303
Updated mechanisms of MASLD pathogenesis
Li, Y., Yang, P., Ye, J., Xu, Q., Wu, J., & Wang, Y. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02108-x · Cited by 300
“Nonalcoholic fatty liver disease (NAFLD) is a metabolic liver injury characterized by excessive deposition of tri-glycerides (TG) in hepatocytes [1, 2].”
BackgroundMetabolic dysfunction-associated steatotic liver disease in adults
Huang, D. Q., Wong, V. W. S., Rinella, M. E., Boursier, J., Lazarus, J. V., Yki-Järvinen, H., & Loomba, R. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00599-1 · Cited by 293
Self-citationChan, S. L., Sun, H.-C., Xu, Y., Zeng, H., El-Serag, H. B., Lee, J. M., Schwartz, M. E., Finn, R. S., Seong, J., Wang, X. W., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01042-6 · Cited by 215
Self-citationLiver cancer in 2021: Global Burden of Disease study
Tan, E. Y., Danpanichkul, P., Yong, J. N., Yu, Z., Tan, D. J. H., Lim, W. H., Koh, B., Lim, R. Y. Z., Tham, E. K. J., Mitra, K., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2024.10.031 · Cited by 232
Self-citationLazarus, J. V., Mark, H. E., Villota-Rivas, M., Palayew, A., Carrieri, P., Colombo, M., Ekstedt, M., Esmat, G., George, J., Marchesini, G., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.025 · Cited by 267
Self-citationNi, Y., Qian, L., Siliceo, S. L., Long, X., Nychas, E., Liu, Y., Ismaiah, M. J., Leung, H., Zhang, L., Gao, Q., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.08.002 · Cited by 216
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world
Henry, L., Paik, J., & Younossi, Z. M. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17158 · Cited by 212
Self-citationA multinational Delphi consensus to end the COVID-19 public health threat
Lazarus, J. V., Romero, D., Kopka, C. J., Karim, S. A., Abu-Raddad, L. J., Almeida, G., Baptista-Leite, R., Barocas, J. A., Barreto, M. L., Bar-Yam, Y., et al. (2022) · Nature · doi:10.1038/s41586-022-05398-2 · Cited by 226
Self-citationClinical practice guidelines for the care of girls and women with Turner syndrome.
Gravholt, C. H., Andersen, N. H., Christin-Maitre, S., Davis, S. M., Duijnhouwer, A., Gawlik, A., Maciel-Guerra, A. T., Gutmark-Little, I., Fleischer, K., Hong, D., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae050 · Cited by 224
An international multidisciplinary consensus statement on MAFLD and the risk of CVD
Zhou, X.-D., Targher, G., Byrne, C. D., Somers, V., Kim, S. U., Chahal, C. A. A., Wong, V. W.-S., Cai, J., Shapiro, M. D., Eslam, M., et al. (2023) · Hepatology International · doi:10.1007/s12072-023-10543-8 · Cited by 194
“Each statement and recommendation was assigned a grade to indicate the level of agreement, using the grading system recorded in other Delphi studies [16, 17]: ‘U’ was unanimous (100%) agreement, ‘A’ was 90–99% agreement, ‘B’ 78–89% was agreement, and ‘C’ was 67–77% agreement.”
MethodSelf-citationHepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology
Huang, D. Q., Singal, A. G., Kanwal, F., Lampertico, P., Buti, M., Sirlin, C. B., Nguyen, M. H., & Loomba, R. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00818-8 · Cited by 189
Self-citationPaik, J. M., Henry, L., Younossi, Y., Ong, J., Alqahtani, S., & Younossi, Z. M. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000251 · Cited by 184
“[63] In addition to the global prevalence rates, our study assessed NAFLD-LRM rates.”
BackgroundSelf-citationTan, D. J. H., Setiawan, V. W., Ng, C. H., Lim, W. H., Muthiah, M. D., Tan, E. X. X., Dan, Y. Y., Roberts, L. R., Loomba, R. S., & Huang, D. Q. (2022) · Hepatology · doi:10.1002/hep.32758 · Cited by 162
Self-citationNon‐alcoholic fatty liver disease and type 2 diabetes: An update
Lee, C., Lui, D. T. W., & Lam, K. S. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13756 · Cited by 158
A global research priority agenda to advance public health responses to fatty liver disease
Lazarus, J. V., Mark, H. E., Allen, A. M., Arab, J. P., Carrieri, P., Noureddin, M., Alazawi, W., Alkhouri, N., Alqahtani, S. A., Arrese, M. A., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.035 · Cited by 149
“In 2021, a global consortium of experts set out consensus recommendations on how to accelerate public health action on this issue.(34) The negative impact of the COVID-19 pandemic on fatty liver disease risk factors(35,36) further reinforces the urgent attention this public health threat requires.”
Self-citationGeographical similarity and differences in the burden and genetic predisposition of NAFLD
Yip, T. C., Gómez, E. V., Petta, S., Yilmaz, Y. N., Wong, G. L., Adams, L. A., de Lédinghen, V., Sookoian, S. C., & Wong, V. W. (2022) · Hepatology · doi:10.1002/hep.32774 · Cited by 136
“Recent efforts in raising disease awareness and developing clinical care pathways are initial steps in the right direction.[217,219,220] Nonetheless, prevention of NAFLD through public education and health policies will be much more important if we are to combat this epidemic.”
BackgroundSelf-citationFan, J., Xu, X., Yang, R.-X., Nan, Y., Wei, L., Jia, J., Zhuang, H., Shi, J., Li, X., Cm, S., et al. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00311 · Cited by 152
Self-citationEskridge, W., Cryer, D. R. H., Schattenberg, J. M., Gastaldelli, A., Malhi, H., Allen, A. M., Noureddin, M., & Sanyal, A. J. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196216 · Cited by 127
Self-citationConsensus Statement on the definition and classification of metabolic hyperferritinaemia
Valenti, L. V. C., Corradini, E., Adams, L. A., Aigner, E. S., Alqahtani, S. A., Arrese, M. A., Bardou‐Jacquet, E., Bugianesi, E., Fernández‐Real, J. M., Girelli, D., et al. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00807-6 · Cited by 122
“%) agreement, ‘A’ 90–99% agreement, ‘B’ 78– 89% agreement and ‘C’ 67– 77% agreement 26 .”
Self-citationHypertension and NAFLD risk: Insights from the NHANES 2017–2018 and Mendelian randomization analyses
Yuan, M., He, J., Hu, X., Yao, L., Chen, P., Wang, Z., Liu, P., Xiong, Z., Jiang, Y., & Li, L. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002753 · Cited by 123
“[2] Although less than 10% of NAFLD patients develop cirrhosis and liver cancer within 10–20 years of diagnosis, this remains a great concern for the medical community given the high prevalence of the disease.”
BackgroundZhong, Q., Zhou, R., Huang, Y., Huang, R.-D., Li, F., Chen, H.-W., Wei, Y.-F., Liu, K., Cao, B., Liao, K.-Y., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.08.024 · Cited by 117
Autophagic lysosome reformation in health and disease
Nanayakkara, R., Gurung, R., Rodgers, S. J., Eramo, M. J., Ramm, G., Mitchell, C. A., & McGrath, M. J. (2022) · Autophagy · doi:10.1080/15548627.2022.2128019 · Cited by 116
“Chronic alcohol intake, a known risk factor for liver steatosis [80], reduces 1388 R.”
BackgroundExosome-Mediated Impact on Systemic Metabolism
Rocha, K. C. E., Ying, W., & Olefsky, J. M. (2024) · Annual Review of Physiology · doi:10.1146/annurev-physiol-042222-024535 · Cited by 112
Duseja, A. K., Singh, S. P., De, A., Madan, K., Rao, P. N., Shukla, A., Choudhuri, G., Saigal, S., Shalimar, S., Arora, A., et al. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.014 · Cited by 117
Self-citationKotsiliti, E., Leone, V., Schuehle, S., Govaere, O., Li, H., Wolf, M. J., Horvatic, H., Bierwirth, S., Hundertmark, J., Inverso, D., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.04.037 · Cited by 108
Self-citationMitrovic, B., Obradovic, M. M., Gluvic, Z. M., Radunovic, M. L., Rizzo, M., Banach, M., & Isenović, E. R. (2022) · Archives of Medical Science · doi:10.5114/aoms/150639 · Cited by 105
“In addition, the prevalence of NASH was confirmed in 20% of subjects with NAFLD [25, 27].”
BackgroundLei, Y., Tang, L., Chen, Q., Wu, L., He, W., Tu, D., Wang, S., Chen, Y., Liu, S., Xie, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34671-1 · Cited by 104
A global action agenda for turning the tide on fatty liver disease
Lazarus, J. V., Mark, H. E., Allen, A. M., Arab, J. P., Carrieri, P., Noureddin, M., Alazawi, W., Alkhouri, N., Alqahtani, S. A., Anstee, Q. M., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000545 · Cited by 104
“[13] Fatty liver disease represents a contemporary public health challenge that requires multidisciplinary and multi-sectoral responses and novel collaboration, from re-orienting health systems to addressing food systems, the built environment, and social deprivation.”
BackgroundMethodInfluentialSelf-citationOxidative Stress in Non-Alcoholic Fatty Liver Disease
Smirne, C., Croce, E., Benedetto, D. D., Cantaluppi, V., Comi, C., Sainaghi, P. P., Minisini, R., Grossini, E., & Pirisi, M. (2022) · Livers · doi:10.3390/livers2010003 · Cited by 109
“The burden varies between and within regions, with the highest prevalence in the Middle East (32%) and South America (30%), and the lowest in Africa (13%) [1].”
BackgroundSun, D., Targher, G., Byrne, C. D., Wheeler, D. C., Wong, V. W., Fan, J., Tilg, H., Yuan, W., Wanner, C., Gao, X., et al. (2023) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-22-421 · Cited by 102
“In the present study, we used a modified Delphi process via an online survey with the goal of reaching a consensus on the link between MAFLD and the risk of CKD (3).”
Self-citationThe global burden of fatty liver disease: the major impact of China
Lou, T.-W., Yang, R., & Fan, J. (2024) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn-23-556 · Cited by 98
Self-citationNuclear receptors linking metabolism, inflammation, and fibrosis in nonalcoholic fatty liver disease
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052668 · Cited by 95
“As awareness of NAFLD is increasing globally [206], ongoing preclinical and clinical studies provided various pathomechanistic insights into disease development and progression, identifying many new potential drug targets [24,207,208].”
BackgroundSelf-citationNAFLD and thyroid function: pathophysiological and therapeutic considerations
Hatziagelaki, E., Paschou, S. A., Schön, M., Psaltopoulou, T., & Roden, M. (2022) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2022.08.001 · Cited by 93
“In addition, obese humans can benefit from bariatric surgery with improved NAFLD due to the efficient body weight reduction [60,61].”
BackgroundMethodSelf-citationTargeting Oxidative Stress with Polyphenols to Fight Liver Diseases
Machado, I. F., Miranda, R. G., Dorta, D. J., Rolo, A. P., & Palmeira, C. M. (2023) · Antioxidants · doi:10.3390/antiox12061212 · Cited by 99
The Growing Economic and Clinical Burden of Nonalcoholic Steatohepatitis (NASH) in the United States
Younossi, Z. M., Paik, J. M., Henry, L. L., Yang, J., Fernandes, G. F., Stepanova, M., & Nader, F. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.12.005 · Cited by 90
Self-citationAdvances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
Yin, X., Guo, X., Liu, Z., & Wang, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032844 · Cited by 99
Wang, Y., Wang, M., Liu, C., Hao, M., Wang, W., Li, Y., Shi, J., Jia, X., Zhang, X., & Dang, S. (2024) · Annals of Medicine · doi:10.1080/07853890.2024.2328521 · Cited by 97
“…weight loss to maintain a normal BMi range to reduce the risk of the metabolic syndrome caused by Nash should be actively promoted worldwide [26,27]. cirrhosis caused by alcohol use still cannot be ignored. according to our analysis, the proportion of alcoholic cirrhosis and its impact on…”
BackgroundSelf-citationNonalcoholic fatty liver disease and cardiovascular diseases: A Mendelian randomization study
Peng, H., Wang, S., Wang, M., Ye, Y., Xue, E. C., Chen, X., Wang, X., Fan, M., Gao, W., Qin, X., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155220 · Cited by 89
Epidemiology and Rb1 gene of retinoblastoma.
Yun, J., Li, Y., Xu, C.-T., & Pan, B.-R. (2011) · International Journal of Ophthalmology · doi:10.3980/j.issn.2222-3959.2011.01.24 · Cited by 103
NASH drug treatment development: challenges and lessons
Tilg, H., Byrne, C. D., & Targher, G. (2023) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00159-0 · Cited by 81
Self-citationKan, C., Zhang, K., Wang, Y., Zhang, X., Liu, C., Ma, Y., Hou, N., Huang, N., Han, F., & Sun, X. (2025) · Annals of Hepatology · doi:10.1016/j.aohep.2025.101898 · Cited by 87
Self-citationSteatotic Liver Disease: Pathophysiology and Emerging Pharmacotherapies
Kokkorakis, M., Muzurović, E. M., Volčanšek, Š., Chakhtoura, M., Hill, M. A., Mikhailidis, D. P., & Mantzoros, C. S. (2024) · Pharmacological Reviews · doi:10.1124/pharmrev.123.001087 · Cited by 86
Cooreman, M. P., Butler, J., Giugliano, R. P., Zannad, F. M., Dzen, L., Huot-Marchand, P., Baudin, M., Beard, D. R., Junien, J., Broqua, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47919-9 · Cited by 83
“Withnofullyapprovedpharmacological therapy, MASH remains a major medical need and public health burden 4,5 .”
Self-citationTerpenoids: Natural Compounds for Non-Alcoholic Fatty Liver Disease (NAFLD) Therapy
Yao, P., & Liu, Y. (2022) · Molecules · doi:10.3390/molecules28010272 · Cited by 78
“Non-alcoholic fatty liver disease (NAFLD) has become a serious public health issue, affecting the health of approximately one-quarter of adults worldwide, causing wide-ranging social and economic implications [1].”
BackgroundStructure-guided discovery of bile acid derivatives for treating liver diseases without causing itch
Yang, J. J. J., Zhao, T., Fan, J., Zou, H., Lan, G., Guo, F., Shi, Y., Ke, H., Yu, H., Yue, Z., et al. (2024) · Cell · doi:10.1016/j.cell.2024.10.001 · Cited by 80
“1,2 Furthermore, nearly one-third of the patients with NAFLD progress to non-alcoholic steatohepatitis (NASH), characterized by hepatic steatosis, inflammation, and fibrosis, which can ultimately culminate in liver cirrhosis and hepatocellular carcinoma, with liver transplantation as the sole viable…”
Self-citationNonalcoholic Fatty Liver Disease: Current Global Burden
El‐Kassas, M., Cabezas, J., Iruzubieta, P., Zheng, M., Arab, J. P., & Awad, A. (2022) · Seminars in Liver Disease · doi:10.1055/a-1862-9088 · Cited by 79
Self-citationRizzo, M., Colletti, A., Penson, P. E., Katsiki, N., Mikhailidis, D. P., Toth, P. P., Gouni‐Berthold, I., Mancini, J., MARAIS, D. P., Moriarty, P. M., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106679 · Cited by 78
Quek, J., Ng, C. H., Tang, A. S. P., Chew, N., Chan, M. Y., Khoo, C. M., Wei, C. P., Chin, Y. H., Tay, P. W. L., Lim, G., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.03.016 · Cited by 80
Self-citationContreras, D., González-Rocha, A., Clark, P., Barquera, S., & Denova‐Gutiérrez, E. (2022) · Annals of Hepatology · doi:10.1016/j.aohep.2022.100873 · Cited by 77
Díaz, L. A., Fuentes–López, E., Ayares, G., Idalsoaga, F. J., Arnold, J., Márquez‐Lomas, A., Ramírez, C., Medel, M. P., Viñuela, F., Lacalle, L., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(22)00008-5 · Cited by 75
Self-citationXu, S., Wu, X., Wang, S., Xu, M., Fang, T., Ma, X., Chen, M., Fu, J., Guo, J., Tian, S., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci166149 · Cited by 74
“…even until it progresses to nonalcoholic steatohepatitis (NASH), the advanced stage of NAFLD featuring hepatic steatosis, inflammation, fibrosis, and liver damage that could ultimately lead to life-threatening sequelae, including cirrhosis, hepatocellular carcinoma (HCC), and liver failure (5, 6).”
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 77
“Treatments that offer cardiovascular protection also should be considered, given that CVD is the leading cause of mortality of patients with NAFLD (22).”
BackgroundSelf-citationEpidemiology of liver diseases: global disease burden and forecasted research trends
Xiao, J., Wang, F., Yuan, Y., Gao, J., Lu, X., Chao, Y., Guo, F., Zhong, J., Che, Z., Li, W., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2722-2 · Cited by 74
“…dysfunction-associated steatotic liver disease (MASLD), which encompasses metabolic complications like diabetes, obesity, and hypertension, is associated with even higher healthcare costs compared to other types of liver diseases (Lazarus et al., 2022; Ma et al., 2021; Rinella et al., 2023).”
Self-citationYounossi, Z. M., Razavi, H. A., Sherman, M., Allen, A. M., Anstee, Q. M., Cusi, K. J., Friedman, S. L., Lawitz, E., Lazarus, J. V., Schuppan, D., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70020 · Cited by 77
Self-citationNew-Onset Age of Nonalcoholic Fatty Liver Disease and Cancer Risk
Liu, C., Liu, T., Zhang, Q., Jia, P., Song, M., Zhang, Q., Ruan, G., Ge, Y., Lin, S., Wang, Z., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.35511 · Cited by 70
“Definition of New-Onset NAFLD NAFLD was defined as (1) the presence of hepatic steatosis diagnosed through imaging (eMethods in Supplement 1), (2) no history of excessive alcohol consumption (ethanol intake <140 g/wk for males and <70 g/wk for females) in the past 12 months, and (3) no competing etiologies for hepatic…”
MethodSelf-citationDanpanichkul, P., Suparan, K., Dutta, P., Kaeosri, C., Sukphutanan, B., Pang, Y., Kulthamrongsri, N., Jaisa-aad, M., Ng, C. H., Teng, M. L. P., et al. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155958 · Cited by 70
Self-citationKim, S., Oh, J. S., Shin, J. I., Aalruz, H., Abbas, N., Babatope, A. E., Aboagye, R. G., Abohashem, S., Abu‐Zaid, A., Addo, I. Y., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(26)00011-7 · Cited by 78
Self-citationAntifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach
Brennan, P. N., Elsharkawy, A. M., Kendall, T. J., Loomba, R., Mann, D. A., & Fallowfield, J. A. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00796-x · Cited by 68
Self-citationEnvisioning how to advance the MASH field
Allen, A. M., Younossi, Z. M., Diehl, A. M., Charlton, M., & Lazarus, J. V. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00938-9 · Cited by 68
Self-citationWhat Do We Know about Inequalities in NAFLD Distribution and Outcomes? A Scoping Review
Talens, M., Tumas, N., Lazarus, J. V., Benach, J., & Pericàs, J. M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215019 · Cited by 65
“NAFLD, like all non-communicable diseases, is a multifactorial disease that is influenced by both individual factors, such as behavior or genetics, and contextual factors such as culture, demographics, income inequality, environment, or health policies [51,53].”
BackgroundSelf-citationGong, P., Long, H., Guo, Y., Wang, Z., Yao, W., Wang, J., Yang, W., Li, N., Xie, J., & Chen, F. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116927 · Cited by 71
Liu, C., Zhu, S., Zhang, J., Wu, P., Wang, X., Du, S., Wang, E., Kang, Y., Song, K., & Yu, J. (2023) · Journal of Gastroenterology · doi:10.1007/s00535-023-02040-4 · Cited by 67
“For example, recent reports found that food insecurity is a new risk factor for steatosis and liver fibrosis, and the continually updated NAFLD consensus, guidelines, and the development of NALC risk stratification tools have laid the foundation for their prevention [53–56].”
BackgroundSelf-citationZhu, C., Huai, Q., Zhang, X., Dai, H., Li, X., & Wang, H. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.78525 · Cited by 68
“NAFLD is the most common chronic liver disease, paralleling the worldwide increase of obesity [1, 2].”
BackgroundImplementation of a liver health check in people with type 2 diabetes
Abeysekera, K. W. M., Valenti, L., Younossi, Z., Dillon, J. F., Allen, A. M., Noureddin, M., Rinella, M. E., Tacke, F., Francque, S., Ginès, P., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(23)00270-4 · Cited by 63
Self-citationCarrieri, P., Mourad, A., Marcellin, F., Trylesinski, A., Calleja, J. L., Protopopescu, C., & Lazarus, J. V. (2022) · Liver International · doi:10.1111/liv.15209 · Cited by 62
Self-citationLncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review
Zeng, Q., Liu, C., Wu, D., Jiang, W., Zhang, N., & Tang, H. (2023) · Biomolecules · doi:10.3390/biom13030560 · Cited by 66
Self-citationThe Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease
Yang, Z., Danzeng, A., Liu, Q., Zeng, C., Xu, L., Mo, J., Ciren, P., Wang, X., Wang, C., Zhang, B., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.87305 · Cited by 65
“Due to the lack of early warning signs, NAFLD can lead to substantial healthcare expenses, economic losses and a significant reduction in health-related quality of life[9, 10].”
BackgroundDíaz, L. A., Lazarus, J. V., Fuentes–López, E., Idalsoaga, F. J., Ayares, G., Desaleng, H., Danpanichkul, P., Cotter, T. G., Dunn, W., Francisco Barrera, M., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00649-x · Cited by 62
Self-citationHuman liver organoids: From generation to applications
Afonso, M. B., Marques, V., van Mil, S. W. C., & Rodrigues, C. M. P. (2024) · Hepatology · doi:10.1097/hep.0000000000000343 · Cited by 61
Soppert, J., Brandt, E. F., Heussen, N. M., Barzakova, E., Blank, L. M., Kuepfer, L., Hornef, M. W., Trebicka, J., Jankowski, J., Berres, M., et al. (2022) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2022.11.030 · Cited by 61
Dua, A., KUMARI, R. R., Singh, M., Kumar, R., Pradeep, S., Ojesina, A. I., & Kumar, R. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1618275 · Cited by 72
Zhu, Q., Li, H., Ao, Z., Xu, H., luo, J., Kaurich, C., Yang, R., Zhu, P., Chen, S., Tang, L., et al. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01540-4 · Cited by 60
“A certain number of individuals with NAFL can develop NASH, which can lead to liver inflammation, and may further progress to the advanced scarring (cirrhosis) and cause liver failure [4, 5].”
BackgroundSelf-citationAdverse Liver Outcomes, Cardiovascular Events, and Mortality in Steatotic Liver Disease
Ochoa‐Allemant, P., Hubbard, R. A., Kaplan, D. E., & Serper, M. (2025) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2025.1809 · Cited by 62
Gómez, E. V., Vuppalanchi, R., Mladenovic, A., Samala, N. R., Gawrieh, S., Newsome, P. N., & Chalasani, N. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.12.029 · Cited by 60
Self-citationNonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease
Hassen, G., Singh, A., Belete, G., Jain, N., la Hoz, I. D., Camacho-Leon, G., Dargie, N. K., Carrera, K. G., Alemu, T., Jhaveri, S., et al. (2022) · Cureus · doi:10.7759/cureus.25495 · Cited by 60
“There are multiple gaps/challenges facing patients, providers, researchers, and stakeholders within the healthcare system which contribute to poor NAFLD outcomes [8,85,90-103].”
BackgroundForlano, R., Stanic, T., Jayawardana, S., Mullish, B. H., Yee, M. S., Mossialos, E. A., Goldin, R. D., Petta, S., Tsochatzis, E. A., Thursz, M. R., et al. (2023) · Liver International · doi:10.1111/liv.15730 · Cited by 58
Self-citationIncidence of liver cancer in young adults according to the Global Burden of Disease database 2019
Danpanichkul, P., Aboona, M. B., Sukphutanan, B., Kongarin, S., Duangsonk, K., Ng, C. H., Muthiah, M. D., Huang, D. Q., Seko, Y., Díaz, L. A., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000872 · Cited by 57
“[51,52] The study highlights challenges related to the availability and quality of primary data, particularly influenced by the vital registration systems in each country.”
Self-citationZheng, Y., Zhao, L., Xiong, Z., Huang, C., Yong, Q., Fang, D., Fu, Y., Gu, S., Chen, C., Li, J., et al. (2024) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.0047 · Cited by 58
Caussy, C., Vergès, B. L., Leleu, D., Duvillard, L., Subtil, F., Klich, A., Hervieu, V., Milot, L. M., Segrestin, B., Bin, S., et al. (2025) · Diabetes Care · doi:10.2337/dc24-2075 · Cited by 57
Xiao, J., Ng, C. H., Chan, K. E., Fu, C., Tay, P., Yong, J. N., Lim, W. H., Tan, D. J. H., Syn, N., Wong, Z. Y., et al. (2023) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.11.006 · Cited by 56
Self-citationAssociation between the cardiometabolic index and NAFLD and fibrosis
Yan, L., Hu, X., Wu, S., Cui, C., & Zhao, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-64034-3 · Cited by 55
Metadata
- Authors
- Lazarus, J. V., Mark, H. E., Anstee, Q. M., Arab, J. P., Batterham, R. L., Castera, L., Cortez-Pinto, H., Crespo, J., Cusi, K., Dirac, M. A., Francque, S., George, J., Hagström, H., Huang, T. T.-K., Ismail, M. H., Kautz, A., Sarin, S. K., Loomba, R., Miller, V., Newsome, P. N., Ninburg, M., Ocama, P., Ratziu, V., Rinella, M., Romero, D., Romero-Gómez, M., Schattenberg, J. M., Tsochatzis, E. A., Valenti, L., Wong, V. W.-S., Yilmaz, Y., Younossi, Z. M., Zelber-Sagi, S., the NAFLD Consensus Consortium, Åberg, F., Adams, L., Khatry, M. S. A., Naamani, K. A., Murillo, O. A., Allen, A. M., Alnaser, F., Alqahtani, S. A., Alswat, K., Alvaro, D., Andrade, R. J., Arrese, M., Awuku, Y. A., Ayesha, M., Baatarkhuu, O., Bakieva, S., Basu, R., Bataller, R., Bedri, S., Bosi, E., Bourliere, M., Bruha, R., Bugianesi, E., Burra, P., Buti, M., Byrne, C. D., Calleja, J. L., Carrieri, P., Carter, F., Fernandez, M. I. C., Castillo-Lopez, G., Castro-Narro, G. E., Chan, H. L. Y., Chan, W.-K., Chang, Y., Colombo, M., Coppell, K. J., Corey, K., Craxi, A., Cryer, D., Dassanayake, A., Martins, A. D. A. S., de Ledinghen, V., DelPrato, S., Demaio, A., Desalegn, H., Dillon, J., Duseja, A., Dorairaj, P., Ekstedt, M., El Kassas, M., Elsanousi, O. M., Esmat, G., Fan, J.-G., Farpour-Lambert, N., Flisiak, R., Fouad, Y., Fuchs, M., Gani, R. A., Gerber, L., Ghazinyan, H., Gheorghe, L., Goh, G. B.-B., Grønbæk, H., Gulnara, A., Hamid, S., Hebditch, V., Hickman, I. J., Hocking, S. L., Hunyady, B., Idilman, R., Isakov, V. A., Jamal, M. H., Jepsen, P., Iskandar, N. J., Song, M. J., Sudhamshu, K. C., Kakizaki, S., Kalamitsis, G., Kanwal, F., Kao, J.-H., Kaplan, L., Kawaguchi, T., Khader, Y., Kim, S. U., Kodjoh, N., Koek, G., Koike, K., Komas, N. P., Korenjak, M., Kugelmas, M., Labidi, A., Lange, N. F., Lavine, J. E., Lazo, M., Lee, N., Lesmana, C. R. A., Liu, C.-J., Long, M. T., Lopez-Jaramillo, P., Malekzadeh, R., Mahtab, M. A., Marchesini, G., Marinho, R., Vázquez, S. E. M., Mateva, L., Nlombi, C. M., Melin, P., Mikolasevic, I., Milovanovic, T., Musso, C., Nakajima, A., Nava, E., Nersesov, A. V., Nikolova, D., Norris, S., Novak, K., Oben, J., Ong, J. P., Onyekwere, C., Papatheodoridis, G., Paruk, I., Patel, K., Macedo, M. P., Penha-Gonçalves, C., Figueroa, M. P., Hofmann, W. P., Petta, S., de Oliveira, C. P. M. S., Puri, P., Pan, C. Q., Rac, M., Ralston, J., Ramji, A., Razavi, H., Alvares-da-Silva, M. R., Roberts, S., Roden, M., Rose, T., Rouabhia, S., Rovere-Querini, P., Rowe, I. A., Sadirova, S., Salupere, R., Saparbu, T., Sayegh, R., Sebastiani, G., Seki, Y., Selmo, J., Serme, A. K., Shaw, J. E., Shenoy, T., Sheron, N., Shibolet, O., Silva, M., Skrypnyk, I., Socha, P., Soriano, J., Spearman, C. W., Sridharan, K., Suárez, J. J., Sheriff, D. S., Sung, K.-C., Swain, M., Tacke, F., Taheri, S., Tan, S.-S., Tapper, E. B., Yki-Järvinen, H., Thiele, M., Shawa, I. T., Tolmane, I., Torres, E. A., Trauner, M., Treeprasertsuk, S., Turcanu, A., Valantinas, J., Vesterhus, M., Waked, I., Wild, S. H., Willemse, J., Wong, R. J., Xanthakos, S., Young, D. Y., Yu, M.-L., Zheng, K. I., Zeybel, M., & Zheng, M.-H.
- Affiliations
- Barcelona Institute for Global Health (ES)
- European Association for the Study of the Liver (CH)
- NIHR Newcastle Biomedical Research Centre (GB)
- Pontificia Universidad Católica de Chile (CL)
- University College London Hospitals NHS Foundation Trust (GB)
- Marqués de Valdecilla University Hospital (ES)
- Veterans Health Administration (US)
- University of Washington (US)
- University of Antwerp (BE)
- The University of Sydney (AU)
- Karolinska Institutet (SE)
- City University of New York (US)
- King Fahd Hospital of the University (SA)
- Institute of Liver and Biliary Sciences (IN)
- University of California San Diego (US)
- University of California, Berkeley (US)
- University Hospitals Birmingham NHS Foundation Trust (GB)
- Makerere University (UG)
- Université Paris Cité (FR)
- Northwestern University (US)
- The Graduate Center, CUNY (US)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- The Royal Free Hospital (GB)
- University of Milan (IT)
- Chinese University of Hong Kong (HK)
- Marmara University (TR)
- Inova Health System (US)
- University of Helsinki (FI)
- The University of Western Australia (AU)
- Mayo Clinic (US)
- Johns Hopkins University (US)
- King Saud University (SA)
- Sapienza University of Rome (IT)
- Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (ES)
- University of Health and Allied Sciences (GH)
- University of KwaZulu-Natal (ZA)
- Mongolian National University of Medical Sciences (MN)
- Ministry of Health of the Republic of Uzbekistan (UZ)
- University of Virginia (US)
- University of Pittsburgh (US)
- Ahfad University for Women (SD)
- Vita-Salute San Raffaele University (IT)
- University of Turin (IT)
- University of Padua (IT)
- University of Southampton (GB)
- Inserm (FR)
- University of the West Indies (BS)
- Universidad de Buenos Aires (AR)
- Union Hospital (HK)
- University of Malaya (MY)
- Kangbuk Samsung Hospital (KR)
- IRCCS Ospedale San Raffaele (IT)
- University of Otago (NZ)
- Harvard University (US)
- University of Kelaniya (LK)
- University of Pisa (IT)
- St. Paul's Hospital Millennium Medical College (ET)
- University of Dundee (GB)
- Post Graduate Institute of Medical Education and Research (IN)
- World Heart Federation (CH)
- Linköping University (SE)
- National Ribat University (SD)
- Cairo University hospitals (EG)
- Shanghai Jiao Tong University (CN)
- Medical University of Białystok (PL)
- Minia University (EG)
- Virginia Commonwealth University (US)
- University of Indonesia (ID)
- Carol Davila University of Medicine and Pharmacy (RO)
- Singapore General Hospital (SG)
- Aarhus University Hospital (DK)
- Aga Khan University (PK)
- British Liver Trust (GB)
- Princess Alexandra Hospital (AU)
- Kuwait University (KW)
- Hlabisa Hospital (ZA)
- Catholic University of Korea (KR)
- National Academy of Medical Sciences (NP)
- National Hospital Organization Takasaki General Medical Center (JP)
- Baylor College of Medicine (US)
- National Taiwan University Hospital (TW)
- Kurume University (JP)
- Jordan University of Science and Technology (JO)
- Yonsei University (KR)
- Université d'Abomey-Calavi (BJ)
- Maastricht University Medical Centre (NL)
- The University of Tokyo (JP)
- Institut Pasteur de Bangui (CF)
- Denver Public Library (US)
- Hôpital La Rabta (TN)
- University Hospital of Bern (CH)
- Columbia University (US)
- Drexel University (US)
- Wilton Park (GB)
- Boston University (US)
- University of Tehran (IR)
- Bangladesh Medical University (BD)
- University of Bologna (IT)
- Centro Hospitalar Lisboa Norte (PT)
- Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (MX)
- University Hospital St. Ivan Rilski (BG)
- University of Kinshasa (CD)
- Favaloro Foundation (AR)
- Yokohama City University (JP)
- Universidad Autónoma de Nuevo León (MX)
- Ss. Cyril and Methodius University in Skopje (MK)
- St. James's Hospital (IE)
- Ljubljana University Medical Centre (SI)
- Guy's Hospital (GB)
- University of the Philippines Manila (PH)
- Lagos State University (NG)
- National and Kapodistrian University of Athens (GR)
- University Health Network (CA)
- Universidade Nova de Lisboa (PT)
- University of Palermo (IT)
- NYU Langone Health (US)
- World Obesity Federation (GB)
- University of British Columbia (CA)
- Center for Disease Analysis (US)
- Alfred Health (AU)
- Düsseldorf University Hospital (DE)
- University of Leeds (GB)
- Tartu University Hospital (EE)
- Kyrgyz State Medical Academy (KG)
- Saint Joseph University (LB)
- McGill University Health Centre (CA)
- Yotsuya Medical Cube (JP)
- Baker Heart and Diabetes Institute (AU)
- King's College London (GB)
- Tel Aviv University (IL)
- Children's Memorial Health Institute (PL)
- Hospital Universitario de La Princesa (ES)
- University of Cape Town (ZA)
- Arabian Gulf University (BH)
- Universidad San Francisco de Quito (EC)
- University of Calgary (CA)
- Charité – Universitätsmedizin Berlin (DE)
- Weill Cornell Medical College in Qatar (QA)
- Hospital Selayang (MY)
- University of Michigan (US)
- University of Southern Denmark (DK)
- University of Malawi (MW)
- Riga East University Hospital (LV)
- University of Puerto Rico, Medical Sciences Campus (PR)
- Medical University of Vienna (AT)
- Chulalongkorn University (TH)
- Nicolae Testemițanu State University of Medicine and Pharmacy (MD)
- Vilnius University Hospital Santariskiu Klinikos (LT)
- Haraldsplass Diakonale Sykehus (NO)
- National Liver Institute (EG)
- University of Edinburgh (GB)
- Stanford Medicine (US)
- Cincinnati Children's Hospital Medical Center (US)
- National University of Singapore (SG)
- Kaohsiung Medical University (TW)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Koç University (TR)
- Corresponding author
- Lazarus, Jeffrey V.
- ORCID
- Lazarus, Jeffrey V.
- Mark, Henry E.
- Anstee, Quentin M.
- Arab, Juan Pablo
- Batterham, Rachel L.
- Castera, Laurent
- Cortez-Pinto, Helena
- Crespo, Javier
- Cusi, Kenneth
- Dirac, M. Ashworth
- Francque, Sven
- George, Jacob
- Hagström, Hannes
- Huang, Terry T.-K.
- Ismail, Mona H.
- Sarin, Shiv Kumar
- Loomba, Rohit
- Miller, Veronica
- Newsome, Philip N.
- Ninburg, Michael
- Ocama, Ponsiano
- Ratziu, Vlad
- Rinella, Mary
- Romero, Diana
- Romero-Gómez, Manuel
- Schattenberg, Jörn M.
- Tsochatzis, Emmanuel A.
- Valenti, Luca
- Wong, Vincent Wai-Sun
- Yilmaz, Yusuf
- Younossi, Zobair M.
- Åberg, Fredrik
- Adams, Leon
- Naamani, Khalid Al
- Allen, Alina M.
- Alqahtani, Saleh A.
- Alswat, Khalid
- Alvaro, Domenico
- Andrade, Raúl J.
- Arrese, Marco
- Awuku, Yaw Asante
- Baatarkhuu, Oidov
- Bakieva, Shokhista
- Basu, Rita
- Bataller, Ramon
- Bedri, Shahinaz
- Bosi, Emanuele
- Bugianesi, Elisabetta
- Burra, Patrizia
- Byrne, Christopher D.
- Carrieri, Patrizia
- Chan, Henry Lik Yuen
- Chan, Wah-Kheong
- Chang, Yoosoo
- Colombo, Massimo
- Coppell, Kirsten J.
- Corey, Kathleen
- Cryer, Donna
- Dassanayake, Anuradha
- Desalegn, Hailemichael
- Dillon, John
- Duseja, Ajay
- Ekstedt, Mattias
- Elsanousi, Osama M.
- Esmat, Gamal
- Fan, Jian-Gao
- Flisiak, Robert
- Fouad, Yasser
- Fuchs, Michael
- Gani, Rino A.
- Gerber, Lynn
- Gheorghe, Liana
- Goh, George Boon-Bee
- Grønbæk, Henning
- Hamid, Saeed
- Hickman, Ingrid J.
- Hocking, Samantha L.
- Jamal, Mohammad H.
- Jepsen, Peter
- Song, Myeong Jun
- Kakizaki, Satoru
- Kanwal, Fasiha
- Kao, Jia-Horng
- Kaplan, Lee
- Kawaguchi, Takumi
- Khader, Yousef
- Kim, Seung Up
- Kodjoh, Nicolas
- Koek, Ger
- Koike, Kazuhiko
- Komas, Narcisse Patrice
- Korenjak, Marko
- Kugelmas, Marcelo
- Labidi, Asma
- Lange, Naomi F.
- Lavine, Joel E.
- Lazo, Mariana
- Lee, Nancy
- Lesmana, Cosmas Rinaldi A.
- Liu, Chun-Jen
- Long, Michelle T.
- Malekzadeh, Reza
- Mahtab, Mamun Al
- Marchesini, Giulio
- Marinho, Rui
- Vázquez, Sophia E. Martínez
- Nlombi, Charles Mbendi
- Musso, Carla
- Nakajima, Atsushi
- Norris, Suzanne
- Oben, Jude
- Ong, Janus P.
- Onyekwere, Charles
- Papatheodoridis, George
- Paruk, Imran
- Patel, Keyur
- Macedo, M. Paula
- Figueroa, Marlene Pérez
- Hofmann, Wolf Peter
- Petta, Salvatore
- Puri, Puneet
- Pan, Calvin Q.
- Ralston, Johanna
- Ramji, Alnoor
- Razavi, Homie
- Roberts, Stuart
- Roden, Michael
- Rowe, Ian A.
- Sadirova, Shakhlo
- Sebastiani, Giada
- Seki, Yosuke
- Shaw, Jonathan E.
- Sheron, Nick
- Shibolet, Oren
- Silva, Marcelo
- Socha, Piotr
- Soriano, Joan
- Spearman, C. Wendy
- Sridharan, Kannan
- Sheriff, Dhastagir Sultan
- Sung, Ki-Chul
- Swain, Mark
- Tacke, Frank
- Taheri, Shahrad
- Tan, Soek-Siam
- Tapper, Elliot B.
- Thiele, Maja
- Shawa, Isaac Thom
- Tolmane, Ieva
- Torres, Esther A.
- Trauner, Michael
- Treeprasertsuk, Sombat
- Turcanu, Adela
- Valantinas, Jonas
- Vesterhus, Mette
- Waked, Imam
- Wild, Sarah H.
- Wong, Robert J.
- Xanthakos, Stavra
- Yu, Ming-Lung
- Zheng, Kenneth I.
- Zheng, Ming-Hua
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2021-10-27
- Volume
- 19
- Issue
- 1
- Pages
- 60-78
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W3208129759
- Cited by
- 757
- References
- 193
- Citations by year
- 2026: 100 · 2025: 156 · 2024: 163 · 2023: 201 · 2022: 127 · 2021: 9
- FWCI
- 19.36
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- UWA Profiles and Research Repository (UWA) (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- ePrints Soton (University of Southampton) (acceptedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- RISalud Institutional Health Repository of Andalucía (submittedVersion, other-oa)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion, other-oa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Falk Foundation
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Alexion Pharmaceuticals
- Alnylam Pharmaceuticals
- Celgene
- City University of New York
- Medpace
- Regeneron Pharmaceuticals
- European Federation of Pharmaceutical Industries and Associations
- Arrowhead Pharmaceuticals
- Medicines Company
- Galecto
- Intercept Pharmaceuticals
- NGM Biopharmaceuticals
- Coherus Biosciences
- National Institute for Health and Care Research (RP-2015-06-005)
- Rosetrees Trust
- Novo Nordisk
- Astellas Pharma
- Shionogi
- European Association for the Study of the Liver
- Novo Nordisk Fonden (NNF18OC0054612)
- Servier
- Julius Clinical
- Genentech
- Allergan
- Novartis Pharma
- Takeda Pharmaceuticals International
- Sanofi-Aventis Deutschland
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Keywords
- non-alcoholic fatty liver disease, public health policy, global health agenda, metabolic syndrome, non-communicable diseases, obesity, health system response, Delphi consensus
- MeSH terms
- Humans, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.